1-tert-butoxycarbonylamino-4-methoxycarbonylaminobutane | 1582265-89-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butoxycarbonylamino-4-methoxycarbonylaminobutane
• 英文别名: tert-butyl N-[4-(methoxycarbonylamino)butyl]carbamate
• CAS: 1582265-89-1
• 化学式: C₁₁H₂₂N₂O₄
• 分子量: 246.307
• InChiKey: KYZRCJGFBVCSFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二碳酸二叔丁酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 22.0h， 生成 1-tert-butoxycarbonylamino-4-methoxycarbonylaminobutane
  参考文献：
  名称：

  Otera催化剂选择性地从氮丙啶上裂解氨基甲酸酯保护基

  摘要：

  发现Otera的双锡氧烷催化剂可促进N保护的氮丙啶对氨基甲酸酯基团的裂解。该方法能够在存在其他N- Cbz基团的情况下对氮丙啶基N-碳苄基氧基（Cbz）基团进行化学选择性切割。选择性是由于通过红外和晶体学分析推断出，氮丙啶基氨基甲酸酯的N-C键更长，更弱。

  DOI：

  10.1071/ch13464

文献信息

• Protein-Polymer-Drug Conjugates
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20130101546A1

  公开（公告）日：2013-04-25

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，该聚合物载体被替换为一个或多个-LD-D，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是分子量≦5 kDa的治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的链接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。
• Terminally Modified Polymers and Conjugates Thereof
  申请人：Mersana Therapeutics, Inc.

  公开号：US20140017265A1

  公开（公告）日：2014-01-16

  A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH 2 ) 2 -L M or —O—CH 2 —CH(OH)—CH 2 —CR 1 ═CR 2 R 3 . L M , R 1 , R 2 , and R 3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种终止修饰的聚合物。聚合物的至少一个端点是—O—（CH2）2-LM或—O—CH2—CH（OH）—CH2—CR1═CR2R3。其中LM，R1，R2和R3在本文中有定义。此外，本文还披露了包括该聚合物和药物有用修饰剂的终端共轭物，以及包括共轭物的组合物、其制备方法以及使用共轭物或其组合物治疗各种疾病的方法。
• HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：EP2931316B1

  公开（公告）日：2019-02-20
• TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF
  申请人：Mersana Therapeutics, Inc.

  公开号：US20170119896A1

  公开（公告）日：2017-05-04

  A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH 2 ) 2 -L M or —O—CH 2 —CH(OH)—CH 2 —CR 1 ═CR 2 R 3 . L M , R 1 , R 2 , and R 3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.